Amgen Inc. (NASDAQ:AMGN) is included among the 13 NASDAQ Stocks with Highest Dividends. On April 10, Morgan Stanley analyst ...

Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen has performed decently but it’s best returns are still ahead.

The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Wall Street recorded a strong performance last week, with benchmark indexes like the Nasdaq Composite, the S&P 500, and the ...

SHANGHAI, April 10 (Reuters) - Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.